Sukaram Thanikan, Maung Soe Thiha, Chongpison Yuda, Jaihan Tassanan, Phathong Chonlada, Chaiteerakij Roongruedee
Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Ma Har Myaing Hospital, Yangon, Myanmar.
Ann Hepatol. 2025 Jan-Jun;30(1):101753. doi: 10.1016/j.aohep.2024.101753. Epub 2024 Dec 7.
FibroTouch® has shown efficacy in staging hepatic fibrosis in patients with chronic viral hepatitis B, but its performance in assessing liver steatosis and fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) patients remains understudied. We aimed to evaluate the diagnostic performance of FibroTouch® in assessing steatosis and fibrosis in the MASLD population.
Liver stiffness measurements and steatosis were assessed using FibroTouch® and FibroScan®, with FibroScan® as the reference standard. Pearson's correlation test evaluated correlations, and kappa statistics determined agreement between the two methods. Optimal cut-off values of FibroTouch® for predicting hepatic steatosis and fibrosis stages were determined through ROC curve analysis with the Youden index method.
Strong correlations were observed between FibroTouch® UAP and FibroScan® CAP (rho=0.74) and LSM values (rho=0.87) (p < 0.001 for both) in a total of 380 patients. The mean CAP value for the entire cohort was 285 ± 51 dB/m, and the median LSM for the cohort was 5 .3kPa. The optimal FibroTouch® UAP cutoffs were 229 dB/m for S0 vs. S1, 267 dB/m for S1 vs. S2, and 294 dB/m for S2 vs. S3. For FibroTouch® LSM, the optimal cutoffs were 6.0 kPa for F0-F1 vs. F2, 7.9 kPa for F2 vs. F3, and 10.6 kPa for F3 vs. F4. Moreover, FibroTouch® effectively assessed hepatic steatosis and fibrosis in patients with different BMIs.
FibroTouch® proved valuable in assessing hepatic steatosis and liver fibrosis staging in MASLD patients, enhancing its applicability in various clinical settings as a suitable and convenient option for MASLD patients.
FibroTouch®已显示出在慢性乙型病毒性肝炎患者肝纤维化分期中的有效性，但其在评估代谢功能障碍相关脂肪性肝病（MASLD）患者肝脏脂肪变性和纤维化方面的表现仍研究不足。我们旨在评估FibroTouch®在评估MASLD人群脂肪变性和纤维化方面的诊断性能。
使用FibroTouch®和FibroScan®评估肝脏硬度测量值和脂肪变性，以FibroScan®作为参考标准。Pearson相关性检验评估相关性，kappa统计量确定两种方法之间的一致性。通过采用约登指数法的ROC曲线分析确定FibroTouch®预测肝脂肪变性和纤维化分期的最佳截断值。
在总共380例患者中，观察到FibroTouch® UAP与FibroScan® CAP（rho = 0.74）和LSM值（rho = 0.87）之间存在强相关性（两者p均<0.001）。整个队列的平均CAP值为285±51 dB/m，队列的中位LSM为5.3kPa。FibroTouch® UAP的最佳截断值为S0与S1对比时为229 dB/m，S1与S2对比时为267 dB/m，S2与S3对比时为294 dB/m。对于FibroTouch® LSM，最佳截断值为F0 - F1与F2对比时为6.0 kPa，F2与F3对比时为7.9 kPa，F3与F4对比时为10.6 kPa。此外，FibroTouch®有效评估了不同BMI患者的肝脏脂肪变性和纤维化。
FibroTouch®在评估MASLD患者肝脏脂肪变性和肝纤维化分期方面被证明具有价值，增强了其在各种临床环境中的适用性，是MASLD患者合适且便捷的选择。
